Natera, Inc.
2 products found
Natera, Inc. products
Oncology Test
Model Signatera - Transforming the Management of Cancer with Personalized Testing
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for cancer management.
Natera - Altera Tumor Profiling
Support treatment decisions with comprehensive tumor profiling. Gain deep insight into the tumor’s genomic alterations and oncology biomarkers with Altera. The detailed sequencing report includes FDA-approved treatments, novel treatment approaches and ongoing clinical trials targeting found mutations. Unlike any other tumor profiling assay, Altera also enables molecular residual disease (MRD) monitoring with the Signatera assay.